Skip to search formSkip to main contentSkip to account menu

LY517717

Known as: LY 517717, LY-517717 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

GlycinePiperazines
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Oral Anticoagulants in Development
Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of… 
Review
2010
Review
2010
Successful applications of computer aided drug discovery: moving drugs from concept to the clinic.
Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Scientific advancements during the… 
Review
2009
Review
2009
New anticoagulants: focus on venous thromboembolism.
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… 
Review
2008
Review
2008
Fragment-Based Approach to Drug Lead Discovery
In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chemistry, has… 
Review
2008
Review
2008
New oral anticoagulants in atrial fibrillation.
  • A. Turpie
  • European heart journal
  • 2008
  • Corpus ID: 16452979
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K… 
Review
2007
Review
2007
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases
  • A. Turpie
  • Arteriosclerosis, thrombosis, and vascular…
  • 2007
  • Corpus ID: 2998452
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing… 
Highly Cited
2007
Highly Cited
2007
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement
Summary.  Background: LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development. 
Review
2006
Review
2006
Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery.
Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of… 
Review
2006
Review
2006
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases
Novel anticoagulants to replace unfractionated heparins, low molecular weight heparins and vitamin K antagonists, are needed… 
Review
2005
Review
2005
Small molecule coagulation cascade inhibitors in the clinic.
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License